Update on Turner and Noonan syndromes

Elizabeth Chacko; Evan Graber; Molly O Regelmann; Elizabeth Wallach; Gertrude Costin; Robert Rapaport

doi:10.1016/j.ecl.2012.08.007

Update on Turner and Noonan syndromes

Endocrinol Metab Clin North Am. 2012 Dec;41(4):713-34. doi: 10.1016/j.ecl.2012.08.007. Epub 2012 Sep 28.

Authors

Elizabeth Chacko¹, Evan Graber, Molly O Regelmann, Elizabeth Wallach, Gertrude Costin, Robert Rapaport

Affiliation

¹ Division of Pediatric Endocrinology and Diabetes, Mount Sinai School of Medicine, New York, NY 10029, USA.

PMID: 23099266
DOI: 10.1016/j.ecl.2012.08.007

Abstract

Turner syndrome (TS) and Noonan syndrome (NS) have short stature as a constant feature; however, both conditions can present clinicians with a challenging array of genetic, cardiovascular, developmental, and psychosocial issues. In recent years, important advances have been achieved in each of these areas. This article reviews these two syndromes and provides updates on recent developments in diagnostic evaluation, growth and development, psychological issues, and treatment options for patients with TS and NS.

Publication types

Review

MeSH terms

Female
Growth Disorders / drug therapy
Growth Disorders / etiology
Growth Hormone / therapeutic use
Humans
Male
Noonan Syndrome* / complications
Noonan Syndrome* / diagnosis
Noonan Syndrome* / physiopathology
Noonan Syndrome* / therapy
Primary Ovarian Insufficiency / drug therapy
Primary Ovarian Insufficiency / etiology
Recombinant Proteins / therapeutic use
Turner Syndrome* / complications
Turner Syndrome* / diagnosis
Turner Syndrome* / physiopathology
Turner Syndrome* / therapy

Substances

Recombinant Proteins
Growth Hormone